Method of treating graft versus host disease with an interleukin-2 mutein

US10654905B2 · kind B2 · utility

Assignees

• The Board of Trustees of the Leland Stanford Junior University · US
• National Institutes of Health, a component of the US Dept. of Health & Human Services · US

Inventors

• Christopher K. Garcia · Menlo Park, US
• Suman Mitra · Bethesda, US
• Warren J. Leonard · Bethesda, US
• Aaron Michael Ring · New Haven, US

Key dates

• Filing date: Oct 30, 2018
• Grant date: May 19, 2020
• Expiry date: Oct 30, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2Rβ receptor and a decreased binding capacity for IL-2Rγc receptor, as compared to wild-type IL-2. Such IL-2 muteins are useful, for example, as IL-2 partial agonist and antagonists in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of graft versus host disease (GVHD) and adult T cell leukemia). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.